---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-354092"
form_type: "8-K"
ticker: "MAZE"
cik: "0001842295"
company_name: "Maze Therapeutics, Inc."
filed_at: "2026-08-17T20:16:30+00:00"
generated_at: "2026-08-17T20:17:27.889972+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Maze Therapeutics appoints Paula Johnson and Sophie Kornowski to board; pipeline milestones ahead

## Summary
- Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., appointed to Maze's board effective Aug 13, 2026.
- Johnson is President of Wellesley College and J&J board member; Kornowski ex-CEO of Boston Pharmaceuticals, led GSK acquisition.
- Board class changes: Nancy Andrews moved to Class II, Hervé Hoppenot to Class III to balance classes.
- CEO Jason Coloma cites upcoming data: MZE829 in AMKD late 2026/early 2027, MZE782 initial data in 2027.
- Each new director receives pro-rata $40k cash retainer and option for 36,000 shares vesting monthly over 3 years.

## SEC filing metadata
- accession: 0001193125-26-354092
- form_type: 8-K
- ticker: MAZE
- cik: 0001842295
- company_name: Maze Therapeutics, Inc.
- filed_at: 2026-08-17T20:16:30+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842295/000119312526354092/0001193125-26-354092-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842295/000119312526354092/d135740d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-354092
- JSON: https://secwatch.observer/filing/0001193125-26-354092.json
- Plain text: https://secwatch.observer/filing/0001193125-26-354092.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.